Dr. Sandip P. Patel

Internal Medicine
1351 Old Freehold Rd, Bay Lea, 
Toms River, NJ 
Accepting New Patients
1351 Old Freehold Rd, Bay Lea, 
Toms River, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sandip Patel is a primary care provider, practicing in Internal Medicine in Toms River, New Jersey. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Gallbladder Cancer, Gallbladder Disease, Tissue Biopsy, and Gastrostomy. Dr. Patel is currently accepting new patients.

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in NJ
Hospital Affiliations
Community Medical Center
Monmouth Medical Center-Southern Campus
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

SHOREMEDICAL5 LLC
1351 Old Freehold Rd, Bay Lea, Toms River, NJ 08753
Other Locations
SHORE MEDICAL SPECIALISTS
9 Hospital Dr, Suite B1, Toms River, NJ 08755
SHOREMEDICAL5 LLC
52 Madison Ave, Ofc 1, Lakewood, NJ 08701
SHOREMEDICAL5 LLC
99 Route 37 W, Community Med Cntr, Toms River, NJ 08755
SHOREMEDICAL5 LLC
2018 State Route 35, Spring Lake, NJ 07762
SHOREMEDICAL5 LLC
1657 Silverton Rd, Toms River, NJ 08753
SHOREMEDICAL5 LLC
600 River Ave, Lakewood, NJ 08701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: TAK-500, Pembrolizumab
Study Phase: Phase 1/Phase 2
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma
Enrollment Status: Terminated
Publish Date: May 06, 2025
Intervention Type: Drug
Study Drug: NIZ985 and Spartalizumab
Study Phase: Phase 1
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Biological
Study Drugs: DSP107, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug, Biological
Study Drugs: SQZ-AAC-HPV, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Suspended
Publish Date: August 18, 2022
Intervention Type: Biological
Study Drugs: NeoTCR-P1 Adoptive Cell Therapy, Nivolumab, IL-2
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 22, 2021
Intervention Type: Drug
Study Drugs: FATE-NK100 Cells, Trastuzumab, Cetuximab
Study Phase: Phase 1
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

288 Total Publications

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).
Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).
Journal: JCO oncology advances
Published: December 08, 2025
Similar Doctors
Distinguished in Severe Acute Respiratory Syndrome (SARS)
Dr. Wei G. Zhao
Internal Medicine
Distinguished in Severe Acute Respiratory Syndrome (SARS)
Dr. Wei G. Zhao
Internal Medicine
3401 N Broad St, 
Philadelphia, PA 
 (50.6 miles away)
267-808-1845
Languages Spoken:
English
See accepted insurances

Wei Zhao is a primary care provider, practicing in Internal Medicine in Philadelphia, Pennsylvania. Dr. Zhao is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Microsporidiosis, Lung Cancer, Lung Adenocarcinoma, Coronary Artery Bypass Graft (CABG), and Osteotomy.

Advanced in Severe Acute Respiratory Syndrome (SARS)
Dr. Jonas Z. Hines
Internal Medicine
Advanced in Severe Acute Respiratory Syndrome (SARS)
Dr. Jonas Z. Hines
Internal Medicine
462 1st Ave, 
New York, NY 
 (53.0 miles away)
212-562-4141
Languages Spoken:
English
See accepted insurances

Jonas Hines is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Hines is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Severe Acute Respiratory Syndrome (SARS), COVID-19, Bacterial Gastroenteritis, and HIV/AIDS.

Advanced in Severe Acute Respiratory Syndrome (SARS)
Dr. Sanjay Kumar
Internal Medicine
Advanced in Severe Acute Respiratory Syndrome (SARS)
Dr. Sanjay Kumar
Internal Medicine

Professional Associates Of Jackson, LLC

2105 West County Line Road, Suite 4, 
Jackson, NJ 
 (38.3 miles away)
732-367-7575
Languages Spoken:
English
See accepted insurances

Sanjay Kumar is a primary care provider, practicing in Internal Medicine in Jackson, New Jersey. Dr. Kumar is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Muscle Atrophy, Acute Kidney Failure, Familial Hypertension, Gastrostomy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 122 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile